EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CRISPR-Editing Therapy for Duchenne Muscular Dystrophy

Francesco Chemello, Eric N Olson, Rhonda Bassel-Duby iD

Human Gene Therapy · 2023-05 · 34 (9-10) · 379-387

DOI: 10.1089/hum.2023.053 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Gene Therapy, online erschienen am 17.05.2023. Verfasst von Francesco Chemello und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is a debilitating genetic disorder that results in progressive muscle degeneration and premature death. DMD is caused by mutations in the gene encoding dystrophin protein, a membrane-associated protein required for maintenance of muscle structure and function. Although the genetic mutations causing the disease are well known, no curative therapies have been developed to date. The advent of genome-editing technologies provides new opportunities to correct the underlying mutations responsible for DMD. These mutations have been successfully corrected in human cells, mice, and large animal models through different strategies based on CRISPR-Cas9 gene editing. Ideally, CRISPR-editing could offer a one-time treatment for DMD by correcting the genetic mutations and enabling normal expression of the repaired gene. However, numerous challenges remain to be addressed, including optimization of gene editing, delivery of gene-editing components to all the muscles of the body, and the suppression of possible immune responses to the CRISPR-editing therapy. This review provides an overview of the recent advances toward CRISPR-editing therapy for DMD and discusses the opportunities and the remaining challenges in the path to clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneMiceHumansAnimalsCRISPR-Cas SystemsGenetic TherapyExonsDystrophinGene EditingDisease Models, Animal

Stichwörter der Autor:innen

AAV vectorsCRISPR-Cas9Duchenne muscular dystrophygene editing

Substanzen

Dystrophin

Autor:innen und Institutionen

  • Department of Biology, University of Padova, Padova, Italy.
  • Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

ORCID-Profile: Rhonda Bassel-Duby

Förderung

  • NICHD NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Chemello, F., Olson, E. N., & Bassel-Duby, R. (2023). CRISPR-Editing Therapy for Duchenne Muscular Dystrophy. Human Gene Therapy, 34(9-10), 379-387. https://doi.org/10.1089/hum.2023.053

Vancouver

Chemello F, Olson EN, Bassel-Duby R. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy. Human Gene Therapy. 2023;34(9-10):379-387. doi:10.1089/hum.2023.053

BibTeX
@article{Chemello2023,
  author = {Chemello, Francesco and Olson, Eric N and Bassel-Duby, Rhonda},
  title = {CRISPR-Editing Therapy for Duchenne Muscular Dystrophy},
  journal = {Human Gene Therapy},
  year = {2023},
  volume = {34},
  number = {9-10},
  pages = {379--387},
  doi = {10.1089/hum.2023.053}
}
Kostenlos starten →